Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

tafasitamab-cxix

View Patient Information
An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities. Tafasitamab-cxix targets and binds to CD19, thereby depleting and eliminating CD19-expressing B cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:immunoglobulin, anti-(human Cd19 antigen) (human-mus musculus monoclonal MOR00208 heavy chain), disulfide with human-mus musculus monoclonal MOR00208 .kappa.-chain, dimer
tafasitamab
US brand name:Monjuvi
Code name:MOR-00208
MOR00208
MOR208
XmAb5574
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search